- Home
- URGN vs FWRG Comparison
URGN vs FWRG Comparison
Compare URGN & FWRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | FWRG |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 975.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | URGN | FWRG |
|---|---|---|
| Price | $19.99 | $16.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $29.50 | $21.56 |
| AVG Volume (30 Days) | 728.3K | ★ 1.3M |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | $96,516,000.00 | ★ $1,169,440,000.00 |
| Revenue This Year | $26.47 | $22.85 |
| Revenue Next Year | $110.65 | $15.22 |
| P/E Ratio | ★ N/A | $201.25 |
| Revenue Growth | 8.00 | ★ 17.27 |
| 52 Week Low | $3.42 | $12.90 |
| 52 Week High | $30.00 | $22.71 |
Technical Indicators
Market Signals| Indicator | URGN | FWRG |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 57.76 |
| Support Level | $18.97 | $15.56 |
| Resistance Level | $22.07 | $16.94 |
| Average True Range (ATR) | 1.31 | 0.56 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 49.24 | 87.97 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.